Sprint Bioscience has sold one of its cancer programs, TREX1, to Gilead Sciences, Inc. The deal includes an upfront payment of USD 14 million and potential milestone payments linked to clinical, regulatory and commercial progress, which could total up to USD 400 million. 

Read more about the deal in the press release of November 24 or a selection of the news articles that reported on the event.

Press release:
Swedish: https://sprintbioscience.com/sv/pressmeddelande/?slug=sprint-bioscience-saljer-trex1-programmet-till-gilead
English: https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-sells-the-trex1-program-to-gilead

News articles:

• 🇺🇸 Fierce Biotech:
  Gilead hatches $400M biobucks deal for Sprint's TREX1 program
• 🇺🇸 Pharmaceutical Technology:
  Gilead snaps up Sprint's TREX1 immunotherapy program for $400m
• 🇺🇸 BioPharma Dive:
  Gilead signs deal with Sprint Bioscience for cancer program TREX1
• 🇬🇧 European Biotechnology:
  Gilead acquires Sprint Bioscience TREX1 program
• 🇩🇪 Financial news:
  Sprint Bioscience Announces Sale Of TREX1 Program to Gilead Sciences
• 🇫🇷 ZoneBourse (French):
  Sprint Bioscience takes off after selling its cancer program to Gilead Sciences

Swedish news articles:

• 🇸🇪 Expressen:
  Rush and crash: Sprint Bioscience rallies while European defense companies plummet
• 🇸🇪 Life Science Sweden:
  Sprint sells cancer project to Gilead - shown significant potential
• 🇸🇪 Dagens Industri:
  Research company soars 135 percent - had several interested parties
• 🇸🇪 BioStock:
  Sprint Bioscience sells TREX1 cancer program to Gilead